title: Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
authors.affiliation: Department of Pharmacy, Local Health Unit, Palermo, Italy.
authors.forename: Maria Elisa
authors.initials: ME
authors.lastname: Barna
authors.forename: Ilaria
authors.initials: I
authors.lastname: Uomo
authors.forename: Maurizio
authors.initials: M
authors.lastname: Pastorello
mesh_terms: D000284:Administration, Oral; D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000068338:Everolimus; D006801:Humans; D007211:Indoles / Q000191:economics / Q000627:therapeutic use*; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D017063:Outcome Assessment, Health Care / Q000191:economics; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011758:Pyrroles / Q000191:economics / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000068338:Everolimus; D000077210:Sunitinib; D020123:Sirolimus